Association between factor V Leiden mutation and the hemiconvulsion, hemiplegia, and epilepsy syndrome: Report of two cases

Journal of Child Neurology

Volumn 17, Issue 9, 2003, Pages 713-717

  Scantlebury, Morris H ^a   David, Michèle ^a   Carmant, Lionel ^b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITY OF MONTREAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 5 LEIDEN; CARBAMAZEPINE; VALPROIC ACID; WARFARIN;

ADOLESCENT; ARTICLE; BRAIN MALFORMATION; CASE REPORT; CEREBRAL PALSY; CONVULSION; EPILEPSY; FEMALE; GENE MUTATION; HEMIPLEGIA; HUMAN; LONG TERM CARE; OCCLUSIVE CEREBROVASCULAR DISEASE; PEDIATRICS; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSENCEPHALY; TREATMENT OUTCOME; VEIN THROMBOSIS;

EID: 0037411993     PISSN: 08830738     EISSN: None     Source Type: Journal    
DOI: 10.1177/088307380201700914     Document Type: Article

References (28)

1. Bertina RM, Koelmann BPC, Koster T, et al: Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64-67.
2. Swenson PJ, Dahlbäck B: Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994;330:517-521.
3. Rees DC: The population genetics of factor V Leiden (ARG506Gln). Br J Haematol 1996;95:579-586.
4. Price DT, Ridker PM: Factor V Leiden mutation and the risks for thromboembolic disease: A clinical perspective. Ann Intern Med 1997;127:895-903.
5. Koster T, Rosendaal FR, de Ronde H, et al: Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993;342:1503-1506.
6. Rosendaal FR, Koster T, Vandenbroucke JP, et al: High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995;85:1504-1508.
7. Rhodeghiero F, Tosetto A: Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism. Ann Intern Med 1999;130:643-650.
8. van Boven HH, Reitsma PH, Rosendaal FR, et al: Factor V Leiden (FV506Q) in families with inherited antithrombin deficiency. Thromb Haemost 1996;75:417-421.
9. Koeleman BP, van Rumpt D, Hamulyak K, et al: Factor V Leiden: An additional risk factor thrombosis in protein S deficient families? Tromb Haemost 1995;74:580-583.
10. Lynch KA, Nelson KB, Curry CJ, et al: Cerebrovascular disorders in children with the factor V Leiden mutation. J Child Neurol 2001;16:735-744.
11. Zenz W, Bodo Z, Plotho J, et al: Factor V Leiden and the prothrombin gene G 20210: A variant in children with ischemic stroke. Thromb Haemost 1998;80:763-766.
12. Gastaut H, Poirier F, Payan H, et al: H.H.E. syndrome: Hemiconvulsions, hemiplegia, epilepsy. Epilepsia 1959;1:418-447.
13. Chevrie JJ, Amsili J, Aicardi J: Acute hemiplegia in infancy and childhood. Dev Med Child Neurol 1969;11:162-173.
14. Kataoka K, Okuno T, Mikawa H, et al: Cranial computed tomographic and electroencephalographic abnormalities in children with post-hemiconvulsive hemiplegia. Eur Neurol 1988;28:279-284.
15. Chevrie JJ, Aiardi J: Consequences of status epilepticus in infants and children. Adv Neurol 1983;34:115-125.
16. Dix EJ, Cail WS: Cerebral hemiatrophy: Classification on the basis of MR imaging findings of mesial temporal sclerosis and childhood febrile seizures. Radiology 1997;203:269-274.
17. Engle J, Pedley T: Epilepsy: A comprehensive textbook, 1st ed. Philidelphia, Lippincott-Raven, 1998, 2292-2295.
18. Aicardi J, Baraton J: A pneumoencephalographic demonstration of brain atrophy following status epilepticus. Dev Med Child Neurol 1971;13:600-657.
19. Roger J, Bureau M, Dravet C, et al: Les données EEG et les manifestations épileptiques en relation avec l'hémiplégie cérébrale infantile. Rev EEG Neurophysiol Clin 1972;2:5-28.
20. Lanthier S, Carmant L, David M, et al: Strokes in children: The coexistence of multiple risk factors predicts poor outcome. Neurology 2000;54:371-378.
21. Deschiens MA, Conrad J, Horellou MH, et al: Coagulation studies, factor V Leiden, and anticardiolipin antibodies in 40 cases of cerebral venous thrombosis. Stroke 1996;27:1724-1730.
22. Lee R: Factor V Leiden: A clinical review. Am J Med Sci 2001; 322:88-102.
23. Eichinger S, Pabinger I, Stumpflen A, et al: The risk of recurrent venous thromboembolism in patients with and without factor V Leiden. Thromb Haemost 1997;77:624-628.
24. Ridcker PM, Miletich JP, Stampfer MJ, et al: Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. Circulation 1995;92:2800-2802.
25. Makris M: Hyperhomocysteinemia is a risk factor for venous and arterial thrombosis. Br J Haematol 1998;101:18-20.
26. McColl MD, Chalmers EA, Thomas A, et al: Factor V Leiden, prothrombin 20210G [→] A and the MTHFR C677T mutations in childhood stroke. Thromb Haemost 1999;81:690-694.
27. Brown K, Luddington R, Baglin T: Effect of the MTHFRC677T variant on the risk of venous thromboembolism: interaction with factor V Leiden and prothrombin (F2G20210A) mutations. Br J Haematol 1998;103:42-44.
28. Lalouscheck W, Aull S, Serles W, et al: C677T MTHFR mutation and factor V Leiden mutation in patients with TIA/minor strokes: A case control study. Thromb Res 1999;93:61-69.